Literature DB >> 32585475

Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.

Cammi Thornton1, Kennedy E Dickson1, Dennis R Carty1, Nicole M Ashpole1, Kristine L Willett2.   

Abstract

Current antiepileptic drugs (AEDs) are undesirable for many reasons including the inability to reduce seizures in certain types of epilepsy, such as Dravet syndrome (DS) where in one-third of patients does not respond to current AEDs, and severe adverse effects that are frequently experienced by patients. Epidiolex, a cannabidiol (CBD)-based drug, was recently approved for treatment of DS. While Epidiolex shows great promise in reducing seizures in patients with DS, it is used in conjunction with other AEDs and can cause liver toxicity. To investigate whether other cannabis-derived compounds could also reduce seizures, the antiepileptic effects of CBD, Δ9-tetrahydrocannabinol (THC), cannabidivarin (CBDV), cannabinol (CBN), and linalool (LN) were compared in both a chemically-induced (pentylenetetrazole, PTZ) and a DS (scn1Lab-/-) seizure models. Zebrafish (Danio rerio) that were either wild-type (Tupfel longfin) or scn1Lab-/- (DS) were exposed to CBD, THC, CBDV, CBN, or LN for 24 h from 5 to 6 days postfertilization. Following exposure, total distance traveled was measured in a ViewPoint Zebrabox to determine if these compounds reduced seizure-like activity. Cannabidiol (0.6 and 1 μM) and THC (1 and 4 μM) significantly reduced PTZ-induced total distance moved. At the highest THC concentration, the significant reduction in PTZ-induced behavior was likely the result of sedation as opposed to antiseizure activity. In the DS model, CBD (0.6 μM), THC (1 μM), CBN (0.6 and 1 μM), and LN (4 μM) significantly reduced total distance traveled. Cannabinol was the most effective at reducing total distance relative to controls. In addition to CBD, other cannabis-derived compounds showed promise in reducing seizure-like activity in zebrafish. Specifically, four of the five compounds were effective in the DS model, whereas in the PTZ model, only CBD and THC were, suggesting a divergence in the mode of action among the cannabis constituents.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabidiol; Dravet syndrome; Epilepsy; Pentylenetetrazole; scn1Lab; Δ9-tetrahydrocannabinol

Mesh:

Substances:

Year:  2020        PMID: 32585475      PMCID: PMC8276876          DOI: 10.1016/j.yebeh.2020.107152

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  47 in total

Review 1.  Advancing epilepsy treatment through personalized genetic zebrafish models.

Authors:  A Griffin; C Krasniak; S C Baraban
Journal:  Prog Brain Res       Date:  2016-04-20       Impact factor: 2.453

2.  Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with No effect on benzodiazepine binding site density.

Authors:  L A Walsh; M Li; T J Zhao; T H Chiu; H C Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

3.  Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Elizabeth A Thiele; Eric D Marsh; Jacqueline A French; Maria Mazurkiewicz-Beldzinska; Selim R Benbadis; Charuta Joshi; Paul D Lyons; Adam Taylor; Claire Roberts; Kenneth Sommerville
Journal:  Lancet       Date:  2018-01-26       Impact factor: 79.321

4.  Neuroprotective effect of kaempferol glycosides against brain injury and neuroinflammation by inhibiting the activation of NF-κB and STAT3 in transient focal stroke.

Authors:  Lu Yu; Chu Chen; Liang-Fen Wang; Xi Kuang; Ke Liu; Hao Zhang; Jun-Rong Du
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

5.  Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.

Authors:  Scott C Baraban; Matthew T Dinday; Gabriela A Hortopan
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

6.  Single and Synergistic Effects of Cannabidiol and Δ-9-Tetrahydrocannabinol on Zebrafish Models of Neuro-Hyperactivity.

Authors:  Éric Samarut; Jessica Nixon; Uday P Kundap; Pierre Drapeau; Lee D Ellis
Journal:  Front Pharmacol       Date:  2019-03-20       Impact factor: 5.810

Review 7.  Building a zebrafish toolkit for investigating the pathobiology of epilepsy and identifying new treatments for epileptic seizures.

Authors:  Vincent T Cunliffe
Journal:  J Neurosci Methods       Date:  2015-07-26       Impact factor: 2.390

8.  Altered Glycolysis and Mitochondrial Respiration in a Zebrafish Model of Dravet Syndrome.

Authors:  Maneesh G Kumar; Shane Rowley; Ruth Fulton; Matthew T Dinday; Scott C Baraban; Manisha Patel
Journal:  eNeuro       Date:  2016-04-05

9.  The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity.

Authors:  Roberto Colangeli; Massimo Pierucci; Arcangelo Benigno; Giuseppe Campiani; Stefania Butini; Giuseppe Di Giovanni
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

10.  A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome.

Authors:  Bláthnaid McCoy; Laura Wang; Maria Zak; Sameer Al-Mehmadi; Nadia Kabir; Kenda Alhadid; Kyla McDonald; Grace Zhang; Rohit Sharma; Robyn Whitney; Katia Sinopoli; O Carter Snead
Journal:  Ann Clin Transl Neurol       Date:  2018-08-01       Impact factor: 4.511

View more
  4 in total

1.  Phenotypic analysis of catastrophic childhood epilepsy genes.

Authors:  Aliesha Griffin; Colleen Carpenter; Jing Liu; Rosalia Paterno; Brian Grone; Kyla Hamling; Maia Moog; Matthew T Dinday; Francisco Figueroa; Mana Anvar; Chinwendu Ononuju; Tony Qu; Scott C Baraban
Journal:  Commun Biol       Date:  2021-06-03

Review 2.  A Review on the Bioactivity of Cannabinoids on Zebrafish Models: Emphasis on Neurodevelopment.

Authors:  Rosario Licitra; Maria Marchese; Valentina Naef; Asahi Ogi; Marco Martinelli; Claudia Kiferle; Baldassare Fronte; Filippo Maria Santorelli
Journal:  Biomedicines       Date:  2022-07-28

3.  In Vivo Evaluation of Cannabis sativa Full Extract on Zebrafish Larvae Development, Locomotion Behavior and Gene Expression.

Authors:  Rosario Licitra; Marco Martinelli; Luigi Petrocchi Jasinski; Maria Marchese; Claudia Kiferle; Baldassare Fronte
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-25

4.  A zebrafish-centric approach to antiepileptic drug development.

Authors:  Scott C Baraban
Journal:  Dis Model Mech       Date:  2021-07-07       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.